🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We are pleased to announce positive initial interim safety and immunogenicity data from our anti-Abeta vaccine ACI-24.060 in Alzheimer's. The ABATE Phase 1b/2 study will now be expanded. Next interim results expected in 2H23. ir.acimmune.com/news-releases/… #vaccination #prevent #Alz

Join AC Immune’s CEO Dr. Andrea Pfeifer, on February 14th, for a Fireside chat at the SVB Securities Global Biopharma Conference and learn more about our Precision Medicine approach and the latest advancements in our clinical-stage vaccines. ir.acimmune.com/events-and-pre… #Alzheimers

We are pleased to announce two new grants, one from the Michael J. Fox Foundation for Parkinson’s Research and one from Target ALS, to support the development of novel diagnostics to detect TDP-43. ir.acimmune.com/news-releases/… #Parkinsons #ALS #diagnostics #MJFF #TargetALS

AC Immune is pleased to report Full Year 2022 Financial Results today. Read the full PR here: ir.acimmune.com/news-releases/… #financialresults #alzheimers #parkinsons #vaccine #prevention

Join us on April 18th at 10:30 AM ET for a KOL webinar with AC Immune on the early diagnosis and prevention of Alzheimer’s and ACIU’s two clinical stage Alzheimer’s vaccines. Register here: lifesci.events/ACIU4 $ACIU

AC Immune is pleased to report First Quarter 2023 Financial Results today. Read the full press release here: ir.acimmune.com/news-releases/… #financialresults #alzheimers #parkinsons #vaccine #prevention

Our anti-Abeta active immunotherapy ACI-24.060 received Fast Track designation from the FDA. In addition, following IND clearance for ACI-24.060, the ongoing ABATE study is expanding to the U.S. and the first person with Down syndrome has now been dosed. ir.acimmune.com/news-releases/…

Join AC Immune ($ACIU) on Thursday, Nov. 9 at 10am ET (4pm CET) for a KOL event featuring Prof. Victor Villemagne, MD who will discuss amyloid plaque PET imaging for Alzheimer’s. ACIU will present the active immunotherapy candidate, ACI-24.060. lifescievents.com/event/acimmune…

AC Immune is pleased to report Q3 2023 Financial results today. Read the full press release here: ir.acimmune.com/news-releases/… #financialresults #alzheimers #parkinsons #prevention

We are delighted to announce that our anti-pTau active immunotherapy ACI-35.030 for #Alzheimer’s advances into the Phase 2b trial ReTain, in collaboration with Janssen Pharmaceuticals Inc., a Johnson & Johnson company. ir.acimmune.com/news-releases/… #precisionmedicine #prevention

We are excited to share that AC Immune will deliver 11 presentations at AD/PD™ 2024 in the beautiful city of Lisbon, Portugal, on March 5 – 9, 2024. ir.acimmune.com/news-releases/… #prevention #PrecisionMedicine #ADPD2024

AC Immune is pleased to report full year 2023 financial results and to provide a corporate update today. Read the full press release here: ir.acimmune.com/news-releases/… #financialresults #alzheimers #parkinsons #prevention #PrecisionMedicine

💙💛Let's celebrate #WorldDownSyndromeDay and #EndTheStereotypes! It's a chance to shine light on individuals living with DS and the health aspects that affect them disproportionately, like Alzheimer's. Join Dr. Rafii, as he delves into this topic: 🔗youtube.com/watch?v=DNrbfl…

We are pleased to announce an exclusive, worldwide option and license agreement for AC Immune’s active immunotherapy targeting Abeta for Alzheimer's disease. Join our conference call today at 8:30 a.m. ET: ir.acimmune.com/events-and-pre…… Read the full PR: ir.acimmune.com/news-releases/…

Join us for a fireside chat at the Jefferies 2024 Global Healthcare Conference to get the latest updates on our clinical-stage active immunotherapy pipeline! Watch the webcast: ir.acimmune.com/events-and-pre… #Alzheimers #Prevention #ActiveImmunotherapy #JefferiesHealthcare #Conference

AC Immune's anti-pTau #active #immunotherapy, ACI-35.030 received FDA Fast Track designation for the treatment of #Alzheimer's, an important recognition of the differentiation and potential value for patients. Full PR here: ir.acimmune.com/news-releases/… #precisionmedicine #prevention

Our collaboration partner Life Molecular Imaging Imaging has received Fast Track Designation for our partnered Tau PET-tracer PI-2620 from the U.S. FDA covering #Alzheimer's disease, progressive supranuclear palsy and corticobasal degeneration. ir.acimmune.com/news-releases/… #fasttrack

We are delighted to announce that we will receive the second Re𝜏ain-related milestone payment of CHF 24.6 million under the agreement with Janssen Pharmaceuticals, Inc. , a Johnson & Johnson company. ir.acimmune.com/news-releases/… #Alzheimers #activeimmunotherapy #prevention

Today, AC Immune reported Q3 2024 financial results and provided a corporate update. Read the full release here: ir.acimmune.com/news-releases/… #financialresults #alzheimers #parkinsons #prevention #precisionmedicine

We are pleased to announce positive interim safety & immunogenicity data from our Ph. 2 VacSYn trial evaluating ACI-7104.056, our wholly owned anti-a-syn #active #immunotherapy for the treatment of early #Parkinson’s disease. ir.acimmune.com/news-releases/… #Prevention #clinicaltrials